ロード中...
Characterization of the anti-CD22 targeted therapy, moxetumomab pasudotox, for B-cell precursor acute lymphoblastic leukemia
Moxetumomab pasudotox is a second-generation recombinant immunotoxin against CD22 on B-cell lineages. Antileukemic activity has been demonstrated in children with chemotherapy-refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL), with variable responses. Here, we report in vitro and in...
保存先:
| 出版年: | Pediatr Blood Cancer |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7501879/ https://ncbi.nlm.nih.gov/pubmed/28449314 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.26604 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|